Brighthouse Q3 EPS $5.21; Merger Outside Date December 6, Extension Talks Underway
BHF is trading near its 52-week low of $41.01 (9.7% above the low).
Summary
Brighthouse reported Q3 net income of $302 million ($5.21 per diluted share) and adjusted earnings of $527 million ($9.12), but the key disclosure is that its $70.00-per-share Aquarian merger will not clear regulatory approvals by the December 6, 2026 Outside Date and the parties are discussing an extension.
Key Events · Earnings and Guidance · BHF
-
Q3 Earnings Boosted by Actuarial Review
Net income available to shareholders was $302 million, or $5.21 per diluted share, versus $453 million, or $7.89, a year earlier; the quarter included a $278 million net favorable impact from the GAAP annual actuarial review.
-
Adjusted Earnings Depend on Notable Items
Adjusted earnings were $527 million, or $9.12 per diluted share, but $314 million ($5.42 per share) of that was favorable notable items, leaving adjusted earnings less notable items of $213 million, or $3.68 per diluted share.
-
Merger Outside Date Set at December 6
The $70.00-per-share, roughly $4.1 billion all-cash Aquarian merger was automatically extended to December 6, 2026; Delaware, New York and Massachusetts insurance approvals are not expected in time, and the parties are discussing amending the agreement to extend the Outside Date, with no assurance an extension is agreed.
-
Capital Position and Sales Trends
Estimated combined RBC ratio was 415%-435%, within the 400%-450% target range but down from 430%-450% at June 30, 2026; holding company liquid assets were $1.0 billion and annuity sales were $2.4 billion, including $2.1 billion of Shield Level Annuities.
Analysis · BHF · Finance
The quarter itself is a modest story: net income of $302 million ($5.21 per diluted share) and adjusted earnings of $527 million ($9.12) both lean heavily on a $278 million favorable GAAP actuarial review and $314 million of favorable notable items, so adjusted earnings excluding notable items were just $213 million ($3.68). For holders, the bigger item is buried in the merger section: the $70.00-per-share Aquarian deal has an Outside Date of December 6, 2026, the required Delaware, New York and Massachusetts insurance approvals are not expected in time, and the parties are negotiating an extension with no assurance one is reached. With the stock at $45.00 against a $70.00 cash price, the market is already pricing meaningful deal-break risk, and this filing confirms the timeline has slipped rather than resolved.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHF was trading at $45.00 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $41.01 to $66.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.